Product Information
AMIODARONE HCL 400 MG TABLET is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $0.4996 per EA under NDC 68382029806. Its NADAC has been published 174 times since Jun 7, 2023.
FDA first approved this application on Sep 16, 2008. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
400 mg/1
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
68382029806
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AMIODARONE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA079029FDA Approved
9/16/2008
TE Code
AB
On Market Since
2/9/2023
Pharmacological Classes
Price Statistics
The NADAC for AMIODARONE HCL 400 MG TABLET has been published 174 times since Jun 7, 2023, and over the history we have for it it has declined 39.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4996 per EA |
|---|---|
| All-time high | $1.7486 (Mar 13, 2024) |
| All-time low | $0.2214 (Aug 21, 2024) |
| 52-week high | $0.4996 |
| 52-week low | $0.3410 |
| Median price | $0.3938 |
| Average price | $0.6211 |
| Largest weekly change | -74.0% (Mar 20, 2024) |
| Weeks tracked | 174 |
| Tracking since | Jun 7, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the amiodarone hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Zydus Pharmaceuticals (USA) Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
amiodarone hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antiarrhythmic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AMIODARONE HCL 400 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for AMIODARONE HCL 400 MG TABLET, manufactured by Zydus Pharmaceuticals (USA) Inc., is $0.4996 per EA (NDC 68382029806), effective Sep 30, 2026.
How has the price of AMIODARONE HCL 400 MG TABLET changed over time?
Over the history we have for it, the NADAC for AMIODARONE HCL 400 MG TABLET has declined 39.1%. It has been tracked across 174 weekly CMS publications since Jun 7, 2023.
What are the highest and lowest recorded NADAC prices for AMIODARONE HCL 400 MG TABLET?
Since Jun 7, 2023, the NADAC for AMIODARONE HCL 400 MG TABLET has ranged from a low of $0.2214 (Aug 21, 2024) to a high of $1.7486 (Mar 13, 2024), with a median of $0.3938 per EA.
Are there cheaper alternatives to AMIODARONE HCL 400 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of AMIODARONE HCL 400 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures AMIODARONE HCL 400 MG TABLET?
AMIODARONE HCL 400 MG TABLET (NDC 68382029806) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.